Skip to main content

Table 1 Basic characteristics of the included trials

From: Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies

First author Clinical trial registration number Year Phase Sample size Gender Age Treatment Disease Assessment (Response) Assessment (AE)
Male Female
Yamamoto, K. NCT00355472 2010 I 16 8 8 62 (46–69) mogamulizumab relapsed CCR4+ ATL or PTCL RECIL CTCAE
Ishida, T. NCT00920790 2012 II 27 12 15 64 (49–83) mogamulizumab relapsed CCR4+ ATL RECIL CTCAE
Ogura, M. NCT01192984 2014 II 37 23 14 64 (33–80) mogamulizumab relapsed CCR4+ PTCL or CTCL RECIL CTCAE
Duvic, M. NCT00888927 2015 I-II 41 24 17 66 (35–85) mogamulizumab CTCL or PTCL RECIL CTCAE
Ishida, T. NCT01173887 2015 II 53 28 25 mLSG15 + mogamulizumab or mLSG15 aggressive ATL RECIL CTCAE
Kurose, K. NCT01929486 2015 I 10 mogamulizumab LC or EC RECIST CTCAE
Zinzani, P. L. NCT01611142 2016 II 38 23 15 58.5 (19–87) mogamulizumab PTCL RECIL CTCAE
Ishitsuka, K. UMIN000025368 2017 II 484 258 226 mogamulizumab or mogamulizumab with other drugs ATL and others RECIL CTCAE
Kim, Y. H. NCT01728805 2018 III 372 216 156 64.5 (54–73) mogamulizumab or vorinostat CTCL RECIL CTCAE
Nakashima, J. 2018 45 27 18 69 (43–89) mogamulizumab relapsed or refractory ATL RECIL CTCAE
Phillips, A. A. NCT01626664 2018 II 34 37 71 53 (22–82) mogamulizumab, pralatrexate, gemcitabine plus oxaliplatin or DHAP ATL RECIL CTCAE
NCT02358473 2018 I 13 5 8 mogamulizumab +docetaxel NSCLC RECIST CTCAE
Doi, T. NCT02476123 2019 I 96 72 24 63 (56–68) mogamulizumab +nivolumab NSCLC, SCLC, GC, EC, HCC, PA RECIST CTCAE
Cohen, E. E. W. NCT02444793 2019 I 24 19 5 63.9 (53–75) mogamulizumab +utomilumab CRC, NSCLC, OC, SCCHN RECIST CTCAE
  1. Abbreviations: ATL adult T-cell leukemia-lymphoma, PTCL peripheral T-cell lymphoma, CTCL cutaneous T-cell lymphoma, LC lung cancer, EC esophageal cancer, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, GC gastric cancer, HCC hepatocellular carcinoma, PA pancreatic adenocarcinoma, CRC colorectal cancer, OC ovarian cancer, SCCHN squamous cell cancer of head and neck, mLSG15 modified LSG15 regimen (VCAP-AMP-VECP: vincristine, cyclophosphamide, doxorubicin and prednisolone; doxorubicin, ranimustine and prednisolone; vindesine, etoposide, carboplatin and prednisolone), AE adverse events, RECIL Response Evaluation Criteria in Lymphoma, RECIST Response Evaluation Criteria in Solid Tumors, CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events